New drug cocktail for breast cancer shows early promise, but trial halted
NCT ID NCT06851442
First seen Jan 05, 2026 · Last updated May 20, 2026 · Updated 19 times
Summary
This study tested a new drug (TQB3912) combined with standard treatments for people with advanced HR-positive, HER2-negative breast cancer. The goal was to find the safest dose and see if the combination could shrink tumors or slow the disease. Only 8 people took part before the trial was stopped early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fuzhou First General Hospital
Fuzhou, Fujian, 350009, China
-
Guizhou Medical University Affiliated Cancer Hospital Co., Ltd
Guiyang, Guizhou, 550001, China
-
Guizhou Provincial People's Hospital
Guiyang, Guizhou, 550002, China
-
Harbin Medical University Cancer
Harbin, Heilongjiang, 150000, China
-
Liaoning Cancer Hospital
Shenyang, Liaoning, 110000, China
-
Meizhou peoples Hospital
Meizhou, Guangdong, 514000, China
-
Ningbo Medical Center Lihuili Hospital
Ningbo, Zhejiang, 315000, China
-
Quanzhou First Hospital
Quanzhou, Fujian, 362000, China
-
Shanxi Cancer Hospital
Taiyuan, Shanxi, 030000, China
-
Taizhou Central Hospital (Taizhou University Affiliated Hospital)
Taizhou, Zhejiang, 31800, China
-
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, 233000, China
-
The First Affiliated Hospital of Xi'an Jiao Tong University
Xi'an, Shaanxi, 710061, China
-
Tianjin Cancer Hospital Airport Hospital
Tianjin, Tianjin Municipality, 300202, China
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, 300202, China
-
Xinjiang Medical University Affiliated Cancer Hospital
Ürümqi, Xinjiang, 830000, China
-
Yongzhou Central Hospital
Yongzhou, Hunan, 425002, China
-
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, 430071, China
Conditions
Explore the condition pages connected to this study.